NIDA Clinical Trials Network: Greater New York Node

项目摘要/摘要 NIDA CTN的大NY节点(GNYN)，由John Rotrosen和Edward共同领导 Nunes，代表2010年纽约和长岛节点的合并，这两个节点一直是CTN的一部分 分别自2000年和2001年以来。这第三个竞争性续订申请建立在强大且成功的 管理临床试验的基础设施，以及创新和成功实施 在主流医疗保健环境中的成瘾管理，在那里可以看到绝大多数的SUD患者。 我们对未来CTN的愿景包括：(1)继续专注于将成瘾管理整合到 主流保健设置和成瘾环境中的医疗条件(例如艾滋病毒、丙型肝炎)的管理， (2)继续注重利用卫生信息技术，包括使用电子健康记录协调 护理和改善结果，(3)不断发展的重点是研究以提供适应性治疗战略和 费用相对较低的基于登记册的务实比较有效性研究，(4)继续侧重于阶段 2/2期研究，其中CTN资源可有效地用于开发新的治疗方法，以及(5)a 专注于-和人口层面的遗传学-临床神经科学-流行病学-和服务的平台 可以进行研究和研究培训。GNYN拥有15年的CTN经验， 支持这一愿景所需的专业知识、资源和合作伙伴。这支球队拥有非凡的广度和 深度和在研究人员之间以及与供应商和 各机构，特别是为拟议研究议程服务的机构。节点具有互补性 在主流医疗保健环境中整合成瘾管理的优势；健康信息 技术、电子健康和移动健康；药物治疗和疫苗开发；行为治疗和 药物-行为联合治疗；艾滋病毒、丙型肝炎和其他感染；共发精神障碍； 预防、早期干预、儿科和青少年；刑事司法人口；吸烟和酗酒； 遗传学、临床神经科学和神经成像；临床试验方法学；以及传播， 实施和可持续性。医疗保健组织包括以大型公立和私立医院为基础的 系统(贝尔维尤医院中心、纽约市卫生和医院公司、西奈山卫生系统、爱因斯坦 Montefiore Health System、VA NY Harbor Healthcare System和SUNY UpState University Health System)、 所有这些都有成瘾治疗服务。传统的专业成瘾项目包括Start， LESC、奥德赛之家、凤凰屋和纳科自由，它们提供了大量的成瘾， 医疗和行为健康服务，并热衷于将护理与主流环境相协调。我们 继续与政策制定者和传播专家接触，包括纽约州立大学和纽约市 DOHMH，纽约市HHC，以及NEC-ATTC和国家成瘾和物质中心 滥用(CASA)，以便他们的投入可以为研究议程提供信息，并促进采用创新。

PROJECT SUMMARY/ABSTRACT The Greater NY Node (GNYN) of the NIDA CTN, under the shared leadership of John Rotrosen and Edward Nunes, represents the 2010 merger of the New York and Long Island Nodes which have been part of the CTN since 2000 and 2001 respectively. This third competing renewal application builds on a strong and successful infrastructure for managing clinical trials and on a track record of innovation and successful implementation of addictions management in mainstream healthcare settings where the vast majority of SUD patients are seen. Our vision for the CTN of the future includes (1) a continued focus on integrating management of addiction in mainstream healthcare settings and management of medical conditions (e.g. HIV, HCV) in addictions settings, (2) a continued focus on leveraging health information technology which includes using EHRs to coordinate care and improve outcomes, (3) an evolving focus on studies to inform adaptive treatment strategies and on relatively low cost registry-based pragmatic comparative effectiveness studies, (4) a continued focus on stage 2 / phase 2 research where CTN resources can be efficiently used to develop new treatments, and (5) a platform on which focused- and population- level genetics-, clinical neuroscience-, epidemiology- and services- research and research training can be conducted. The GNYN has 15 years of CTN experience, and the expertise, resources and partners necessary to support this vision. The team has exceptional breadth and depth and an established track-record of collaboration both amongst researchers and with providers and institutions, particularly in the service of the proposed research agenda. The Node has complementary strengths in integration of addictions management in mainstream healthcare settings; health information technology, eHealth and mHealth; pharmacotherapy and vaccine development; behavioral therapy and combined medication-behavioral treatments; HIV, HCV and other infections; co-occurring psychiatric disorders; prevention, early intervention, pediatrics and adolescents; criminal justice populations; smoking and alcohol; genetics, clinical neuroscience and neuroimaging; clinical trials methodology; and dissemination, implementation and sustainability. Healthcare organizations include large public and private hospital-based systems (Bellevue Hospital Center, NY City Health and Hospitals Corp, Mount Sinai Health System, Einstein Montefiore Health System, VA NY Harbor Healthcare System and SUNY Upstate University Health System), all of which have addictions treatment services. Traditional specialty addictions programs include START, LESC, Odyssey House, Phoenix House and Narco Freedom, which provide a great range of addictions, medical and behavioral health services and which are keen to coordinate care with mainstream settings. We continue to engage policy-makers and dissemination experts, including the NY State OASAS, the NY City DOHMH, the NY City HHC, as well as the NeC-ATTC, and the National Center on Addiction and Substance Abuse (CASA), so that their input can inform the research agenda and foster adoption of innovation.